HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.

Journal Article (Journal Article)

CCR5 antagonists are a new class of antiretroviral drugs that block viral entry by disrupting interactions between the viral envelope (Env) glycoprotein and coreceptor. During the CCR100136 (EPIC) Phase IIb study of the CCR5 antagonist aplaviroc (APL) in treatment-naive individuals, a patient was identified who harbored virus strains that exhibited partial resistance to APL at the time of virologic failure. Retrospectively, it was found that APL resistance was present at baseline as well. To investigate the mechanism of APL resistance in this patient, we cloned HIV-1 env genes from plasma obtained at baseline and after virologic failure. Approximately 85% of cloned Envs were functional, and all exhibited partial resistance to APL. All Envs were R5-tropic, were partially resistant to other CCR5 antagonists including maraviroc on cells with high CCR5 expression, but remained sensitive to the fusion inhibitor enfuvirtide. Competition studies with natural CCR5 ligands revealed that the mechanism of drug resistance entailed the use of the drug-bound conformation of CCR5 by the Env proteins obtained from this individual. The degree of drug resistance varied between Env clones, and also varied depending on the cell line used or the donor from whom the primary T cells were obtained. Thus, both virus and host factors contribute to CCR5 antagonist resistance. This study shows that R5 HIV-1 strains resistant to CCR5 inhibitors can arise in patients, confirming a mechanism of resistance previously characterized in vitro. In addition, some patients can harbor CCR5 antagonist-resistant viruses prior to treatment, which may have implications for the clinical use of this new class of antiretrovirals.

Full Text

Duke Authors

Cited Authors

  • Tilton, JC; Amrine-Madsen, H; Miamidian, JL; Kitrinos, KM; Pfaff, J; Demarest, JF; Ray, N; Jeffrey, JL; Labranche, CC; Doms, RW

Published Date

  • January 2010

Published In

Volume / Issue

  • 26 / 1

Start / End Page

  • 13 - 24

PubMed ID

  • 20055594

Pubmed Central ID

  • PMC2858898

Electronic International Standard Serial Number (EISSN)

  • 1931-8405

Digital Object Identifier (DOI)

  • 10.1089/aid.2009.0132


  • eng

Conference Location

  • United States